Research Projects All Projects

Quick links

Usage of conservative borrelia protein as vaccine target

Project Title: „Usage of conservative borrelia protein as vaccine target”

Funding: European Regional Development Fund (ERDF), Measure “Support for applied research”

Project No.:

Period: 1 March 2021 – 30 November 2023

Project costs: 540 540.54 EUR

Principle Investigator: Dr. biol. Kaspras Tārs

Cooperation partner: AS “Biotehniskais centrs” 


Project summary:

The aim of the project is to produce chromosome encoded conservative Borrelia protein and test its efficacy as vaccine candidate against Lyme disease in mice model.

To achieve our aim, we propose to use borrelial protein BBH0689 as antigen. BBH0689 will be produced as recombinant proteins in E. coli. To enhance the immune response, we plan to conjugate the obtained protein to virus-like particles (VLPs) of ssRNA phages.

Lyme disease is the most prevalent tick-born disease in Europe and North America, with about 400,000 registered cases annually. Disease may have different complications – pain in joints, neurological disorders, symptoms like multiple sclerosis and arthritis. Although the disease can be cured with antibiotics, symptoms may persist for years even after antibiotic treatment. Currently, no vaccine against Lyme disease is available in the market. In 1998, Smith Kline Beecham Biologicals (now part of GlaxoSmithKline) developed LYMErix anti-Lyme disease vaccine, but it was removed from the market due to complaints about side-effects and multiple lawsuit cases.

Information published 01.03.2021.

Mājas lapas izstrādi finansēja ERAF aktivitātes projekts Nr. 2010/0196/2DP/ "Latvijas biomedicīnas pētījumu integrācija Eiropas zinātnes telpā".